Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male started using topical finasteride (0.25%) and minoxidil (5%) once daily, along with supplements like zinc, magnesium, biotin, and vitamins C and D. After initial concerns about side effects, he experienced temporary ED and shedding but now feels better and has no regrets about starting the treatment.

The conversation discusses hair loss treatments, specifically the use of finasteride, dutasteride, and RU58841. The user is seeking alternatives after finasteride failed to stop hair loss, with suggestions to try dutasteride or consider RU58841 under caution.

The post and conversation are about a 23-year-old deciding to stop using finasteride for hair loss due to potential erectile dysfunction risks, sparking a debate about the benefits and side effects of hair loss treatments.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The user experienced hair loss and itching after stopping RU58841 and resumed it to stop these symptoms. They also use Dutasteride and question which treatment is effective.

A 17-year-old male experiencing significant hair loss is using a prescribed topical treatment containing Minoxidil, Tretinoin, Dutasteride, and Latanoprost. He expresses concerns about the potential side effects of Dutasteride and oral Finasteride, and seeks advice on whether to continue with the treatment or consider alternatives.

A 26-year-old man who had a hair transplant and used minoxidil with good results is now experiencing shedding and considering finasteride. He's concerned about high progesterone and mild erectile dysfunction before starting the treatment.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

A user experienced significant hair loss despite using Dutasteride and RU58841 for three years, questioning the effectiveness of these treatments. They are considering a scalp biopsy to explore other potential causes of hair loss.